HENLIUS (02696) surged over 4%, reaching HK$67.1 by the time of writing, with a trading volume of HK$31.4 million. The company, in collaboration with Organon, announced that the Biologics License Application (BLA) for pertuzumab injection POHERDY has been approved by the U.S. Food and Drug Administration (FDA). POHERDY is now the first and only biosimilar to PERJETA in the U.S., interchangeable with the reference product and covering all its approved indications. Notably, POHERDY is the first pertuzumab biosimilar in the U.S. and the first FDA-approved interchangeable biosimilar for cancer treatment. Additionally, HLX11 has submitted marketing applications in China, Europe, and Canada, which have been accepted. To date, HENLIUS has secured overseas approvals for seven products, including four in the U.S.